新規抗ウイルス剤，ブロバビル（ＢＶアラＵ）のｉｎ　ｖｉｔｒｏ抗ヘルペス作用

DOI

書誌事項

タイトル別名
  • In vitro anti-herpes virus action of a novel antiviral agent, brovavir (BV-araU).

抄録

We tested the antiviral action of 1-β-D-arabinofuranosyl-E-5-(2-bromovinyl) uracil (brovavir) on herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), varicella-zoster virus (VZV) and human cytomegalovirus by a plaque reduction method on human embryo lung cells. Acyclovir, bromoviny1-2'-deoxyuridine, idoxuridine and vidarabine (are A) were used as control drugs. Brovavir exhibited extremely marked antiviral activity against all five strains of VZV and significant activity against all seven strains of HSV-1. Average ED50 values of brovavir for VZV and HSV-1 were 0.4 and 22 ng/ml, respectively. Brovavir was most potent against VZV and HSV-1 of the antiviral drugs tested. Based on the ED50 value, brovavir was over 2, 000 times more active than acyclovir, and about 4, 000 times more active than vidarabine against VZV. On the other hand, brovavir showed marginal or no effect on HSV-2 plaque formation and little effect on human cytomegalovirus. We consider brovavir a potential candidate for clinical application as a novel antiherpes drug in the treatment of HSV-1 and VZV infections, particularly herpes zoster.

収録刊行物

キーワード

詳細情報 詳細情報について

  • CRID
    1390001206277848448
  • NII論文ID
    130004197092
  • DOI
    10.11250/chemotherapy1953.38.256
  • ISSN
    18845894
    00093165
  • 本文言語コード
    ja
  • データソース種別
    • JaLC
    • CiNii Articles
  • 抄録ライセンスフラグ
    使用不可

問題の指摘

ページトップへ